1 Introduction
==============

Knowing the molecular targets of a drug or chemical compound is crucial in the drug discovery research for, among other things, identifying therapeutic properties and side effects, understanding the mechanism of action of a drug, finding alternative compounds with similar or greater efficacy and exploring new applications of a drug for treatment of other diseases (drug repositioning). In this regard, advances in high-throughput omics technology have been playing a crucial role in providing the data for elucidating cellular entities which interact with drug and chemical compounds. Cellular-wide response such as whole-genome gene expression profile, to genetic perturbations and chemical compounds can now be measured easily and cheaply. Furthermore, large amount of omics data are available from the ever-growing public biological databases. Because such data are typically of high dimensionality, the use of computational methods has become necessary in their analysis, for example in the inference of gene regulatory networks ([@btw148-B18]).

Computational systems biology has provided many tools to analyze gene expression profiles for drug target predictions. A summary of different methods in this topic can be found in a review article ([@btw148-B8]). Briefly, there exist two main strategies: comparative analysis and network analysis. In comparative analysis, the gene targets are determined by comparing the gene expression profiles under drug treatments of interest with those from experiments with known genetic perturbations. This strategy generally involves gathering a compendium of expression profiles from genetic perturbations and chemical compound treatments with known mechanisms, followed by an association analysis of the expression profiles from drugs (e.g. using clustering, distance or connectivity score) ([@btw148-B17]; [@btw148-B27]; [@btw148-B19]). A strong degree of association suggests a high similarity between the molecular targets of a drug of interest and the known perturbations.

In network analysis strategy, a model of the GRN is employed to predict GRN perturbations caused by drugs. The perturbation analysis requires constructing a network model of gene transcriptional regulation. One class of network analysis called network filtering is based on an ordinary differential equation (ODE) model of the gene transcription process. By taking the steady state assumption, the inference of GRN and drug targets reduces to solving a multivariate linear regression problem (see Methods and Materials for more details). Algorithms from this class of network analysis include network identification by multiple regression (NIR) ([@btw148-B14]), mode of action by network identification (MNI) ([@btw148-B10]) and sparse simultaneous equation model (SSEM) ([@btw148-B9]). Here, the gene target predictions are obtained by first inferring the GRN using a library of gene expression data from the same species or cell line. Subsequently, the inferred GRN is used to filter the expression data of drug treatments. More precisely, genes with expressions which could not be explained by the transcriptional activity of their regulators are scored more likely to be direct targets of the drug.

Another type of network analysis methods rely on statistical test or enrichment analysis of the gene expression profiles to identify drug targets. One strategy called reverse causal reasoning uses literature-mined gene regulatory networks to generate hypotheses, which are subsequently scored against the gene expression profile ([@btw148-B2]; [@btw148-B7]; [@btw148-B32]). Another set of methods employ a transcription factor (TF) enrichment analysis followed by an upstream analysis, which involves a search for proteins that are highly connected to enriched TFs in signal transduction or protein-protein interaction networks ([@btw148-B5]; [@btw148-B23]; [@btw148-B25]; [@btw148-B26]). Meanwhile, a method called Master Regulatory Inference algorithm (MARINa) applies gene set enrichment analysis using a transcriptional regulatory network to identify TFs whose regulons are enriched for differentially expressed genes ([@btw148-B28]). Finally, a recent algorithm named Detecting Mechanism of Action by Network Dysregulation (DeMAND) uses an input GRN and expression data from control and drug treatments to identify target genes based on dysregulated gene interactions ([@btw148-B43]). Despite the differences in how GRNs are used in network analysis methods, the accuracy of the target predictions naturally depend on the fidelity of the GRN model. Unfortunately, the inference of GRN is known to be very challenging as the problem has been shown to be underdetermined ([@btw148-B36]; [@btw148-B41]).

In this work, we developed a network analysis method called DeltaNet for predicting the genetic perturbations caused by a drug or chemical compound using gene expression profiles. DeltaNet is also based on an ODE model of the GRN, but does not require a separate step of GRN inference. Instead, the target predictions are obtained directly from the data, while the GRN is only inferred implicitly. DeltaNet relies on the least angle regression (LAR) ([@btw148-B11]) and the LASSO regularization ([@btw148-B40]) to tackle the curse of dimensionality of the underlying regression problem. We demonstrated the advantages of DeltaNet over *z*-scores and other network filtering methods, namely MNI and SSEM, using compendia of gene expression data from *Escherichia coli*, *Saccharomyces cerevisiae*, *Drosophila melanogaster* and *Homo sapiens*.

2 Methods and materials
=======================

2.1 DeltaNet formulation
------------------------

DeltaNet is based on the following ODE model of gene transcriptional process ([@btw148-B29]): $$\frac{dr_{k}}{dt} = u_{k}{\prod\limits_{j = 1}^{n}{r_{j}{}^{a_{kj}} - d_{k}r_{k}}}$$ where *r~k~* denotes the mRNA concentration of gene *k*, $u_{k}$ and $d_{k}$ denote the mRNA transcription and degradation rate constants of gene *k*, respectively, $a_{kj}$ denotes the regulatory control of gene *j* on gene *k*, and *n* denotes the total number of genes. The sign of $a_{kj}$ describes the nature of the regulatory control, where a positive (negative) value represents activation (inhibition). Meanwhile, the magnitude of $a_{kj}$ corresponds to the strength of the regulation. We assume that $a_{kk} = 0$, i.e. there exists no direct self-regulatory loop. While this assumption may appear limiting, the case studies showed that DeltaNet could accurately predict network perturbations across different species. Under the steady state assumption, the concentration change of mRNA over time $dr_{k}/dt$ can be set to 0, which simplifies the model above into $$r_{k} = \frac{u_{k}}{d_{k}}{\prod\limits_{j = 1}^{n}{r_{j}{}^{a_{kj}}}} = g_{k}{\prod\limits_{j = 1}^{n}r_{j}^{a_{kj}}}$$ where $g_{k} = u_{k}/d_{k}$ is the ratio between mRNA transcriptional and degradation rate constants.

Gene expression data of a treatment are typically reported as ratios with respect to readings from the corresponding control experiments. One can rewrite the model above for gene expression ratios (dividing both sides of [Eq. (2)](#E2){ref-type="disp-formula"} by the mRNA level in the control experiment), as follows: $$\frac{r_{ki}}{r_{kb_{i}}} = \left( \frac{g_{ki}}{g_{kb_{i}}} \right){\prod\limits_{j = 1}^{n}\left( \frac{r_{ji}}{r_{jb_{i}}} \right)^{a_{kj}}}$$ where $r_{ki}$ and $r_{kb_{i}}$ denote the mRNA levels of gene *k* in treatment sample *i* and in the corresponding control experiment $b_{i}$, respectively. The model formulation in [Eq. (3)](#E3){ref-type="disp-formula"} relies on the implicit assumption that the drug treatment affects only mRNA transcriptional and/or degradation rate constants without causing any changes in the GRN. Therefore, some care should be taken when applying DeltaNet and related methods such as MNI and SSEM to any treatments that may rewire the GRN.

Taking the logarithm of both sides of [Eq. (3)](#E3){ref-type="disp-formula"} leads to the following linear expression: $$c_{ki} = {\sum\limits_{j = 1}^{n}{a_{kj}c_{ji}}} + p_{ki}$$ where $c_{ki} = \log(r_{ki}/r_{kb_{i}})$ denotes the log-fold change (logFC) of mRNA level of gene *k* and $p_{ki} = \log(g_{ki}/g_{kb_{i}})$ denotes the effects of treatment in sample *i*. Typically, a base-2 logarithm is employed in the analysis of gene expression data ([@btw148-B37]). According to [Eq. (4)](#E4){ref-type="disp-formula"}, the logFC of gene transcript *k* in a given sample comes from a contribution of two factors: (i) changes in the expression of genes that regulate gene *k* and (ii) a direct perturbation on the effective transcription (i.e. the ratio between transcription and degradation) of gene *k* by the treatment. A positive (negative) perturbation variable $p_{ki}$ indicates that the effective transcription of gene *k* is increased (decreased) by the treatment.

Several network filtering methods have been formulated based on [Eq. (4)](#E4){ref-type="disp-formula"}, such as NIR, MNI and SSEM ([@btw148-B9]; [@btw148-B10]; [@btw148-B14]). In these methods, the inference of gene targets of a treatment is performed in two steps. The first step involves the identification of GRN, i.e. the coefficients $a_{kj}$, using gene expression data from experiments with known genetic perturbations (e.g. gene knock-out or silencing) and/or data compiled from publicly available database. In the second step, the perturbations $p_{ki}$ are calculated for the treatment samples of interest by network filtering using the GRN identified in the first step. Consequently, the predictions of gene targets depend on the GRN inference, a problem that is known to be severely underdetermined ([@btw148-B36]; [@btw148-B41]).

In contrast, DeltaNet generates the target prediction in a single step based on rewriting [Eq. (4)](#E4){ref-type="disp-formula"} in a matrix-vector format, as follows: $$C = AC + P = \begin{bmatrix}
A & P \\
\end{bmatrix}\begin{bmatrix}
C \\
I_{m} \\
\end{bmatrix}$$ where *C* is the $n \times m$ matrix of logFC gene expression data of *n* transcripts from *m* samples, *A* is the $n \times n$ matrix of the coefficients $a_{kj}$ (with zero diagonal entries), *P* is the $n \times m$ matrix of treatment effects or perturbations $p_{ki}$, and $I_{m}$ is the $m \times m$ identity matrix. Here, we estimate the coefficients of the matrices *A* and *P* simultaneously by solving the linear regression problem: $$C^{T} = \begin{bmatrix}
C^{T} & I_{m} \\
\end{bmatrix}\begin{bmatrix}
A^{T} \\
P^{T} \\
\end{bmatrix}$$ Since the dimension of the unknowns is larger than the number of samples, the regression problem above is underdetermined. We employ two different strategies for solving [Eq. (6)](#E6){ref-type="disp-formula"}. The first involves least angle regression, which is a particularly efficacious model variable selection algorithm for low-sample high-dimensional data ([@btw148-B11]). In the second implementation, we use LASSO regularization by constraining the L~1~-norm of the solution ([@btw148-B40]). The details of DeltaNet implementations are given in the next section.

2.2 DeltaNet implementation
---------------------------

In the implementation of DeltaNet, we treat [Eq. (6)](#E6){ref-type="disp-formula"} as a general linear regression problem: $$Y = XB$$ where $X = \begin{bmatrix}
C^{T} & I_{m} \\
\end{bmatrix}$, $Y = C^{T}$ and $B = \begin{bmatrix}
A & P \\
\end{bmatrix}^{T}$. The columns of *X* and *Y* are further centered to have zero mean, while those of *X* are also normalized to have a unit Eucledian norm. The matrix *B* could be solved one column at a time, i.e. the matrices *A* and *P* are obtained one gene at a time. Thereby, DeltaNet involves solving multiple independent linear regression problems of the type $y_{k} = X\beta_{k}$, which can be easily parallelized for computational speed-up. In order to enforce *a~kk~* = 0, we set the (*k*th) row of the data matrix *C* corresponding to gene *k* to zero when solving $\beta_{k}.$ The matrix *A*, if desired, can be computed by rescaling the appropriate submatrix of *B*. Meanwhile, the matrix *P* is taken from the solution for *B* without rescaling.

Two versions of DeltaNet are available: DeltaNet-LAR and DeltaNet-LASSO. As the name suggests, DeltaNet-LAR uses the LAR algorithm to solve the underdetermined regression problem above. LAR is an algorithm developed for creating sparse linear models ([@btw148-B11]). Like the traditional forward selection method, LAR starts with a zero vector as the initial solution (i.e. no active variables), and adds a new predictor variable (i.e. an active variable) at every step. LAR employs a less greedy algorithm than the forward selection method in calculating the coefficients of the active variables. Briefly, in the first iteration, we choose the predictor that correlates most with the data (i.e. one that forms the least angle with the residual vector) and add this variable to the active set. The solution is updated along the direction of equal angles with respect to all variables in the active set, until the residuals become equally correlated with another predictor which is outside the active set. In the next iteration, this predictor is added to the active set, and the process is repeated until completion or until a desired number of active variables is reached.

We employ the LAR algorithm from the MATLAB toolbox SpaSM (Sparse Statistical Modeling) (<http://www2.imm.dtu.dk/projects/spasm/>). In a typical scenario, LAR terminates after *m* or fewer steps, since the number of samples *m* is far fewer than the number of genes in the dataset. The output of LAR consists of a series of solution vectors $\beta_{k}^{i}$, $i = 1,\, 2,\cdots,\, I$, where *I* is the total number of steps. In DeltaNet-LAR, the steps are carried out until the relative norm error $\left\| {y_{k} - X\beta_{k}^{i}} \right\|/\left\| y \right\|$ falls below a user-defined stopping criterion *δ~r~*. Setting *δ~r~* higher would lead to fewer steps taken in LAR and thus fewer non-zero coefficients in the solution vector $\beta_{k}.$ The case studies below showed that the accuracy of DeltaNet predictions does not depend strongly on *δ~r~* in the range of 1% ≤ *δ~r~* ≤ 10%. A higher *δ~r~* has the benefit of reducing computational time at the trade-off of slightly reduced prediction accuracy (see Section 3).

In DeltaNet-LASSO, we solve the following penalized minimization problem: $${\min\limits_{\beta_{k}}\left\| {y_{k} - X\beta_{k}} \right\|_{2}}{\text{subject\ to}\left\| a_{k} \right\|_{1} \leq T}$$ where *a~k~* is the *k*th row vector of the *A* matrix. Here, we employ GLMNET ([@btw148-B13]) to generate a regularization path for the LASSO problem above. Briefly, GLMNET uses the cyclical coordinate descent algorithm, which successively minimizes the objective function one-parameter-at-a-time and cycles over the parameters until convergence. While LAR could also be modified to generate the regularization path for LASSO ([@btw148-B11]), our experience showed that GLMNET could reduce the computational times by several folds. For DeltaNet-LASSO, we implemented GLMNET subroutines for MATLAB ([http://www.stanford.edu/∼hastie/glmnet_matlab](http://www.stanford.edu/&sim;hastie/glmnet_matlab)/).

We perform a *k*-fold cross validation (CV) method to determine the optimal *T* value. Briefly, we randomly divide the data into *k* equal-sample parts. For each CV trial, we assign *k --* 1 parts as the training set and the remaining part as the test set. We then generate the regularization path using GLMNET and evaluate the errors of predicting the test set data as a function of *T* by rescaling the appropriate subvector of $\beta_{k}$ to *a~k~*. The optimal *T* corresponds to the minimum average test errors over *k* number of CV trials.

[Figure 1](#btw148-F1){ref-type="fig"} illustrates the general workflow of DeltaNet. In the first case study, we evaluated the performance of DeltaNet in predicting known gene perturbations in *Escherichia coli*, *Saccharomyces cerevisiae* (yeast) and *Drosophila melanogaster* (fruit fly). In the second case study, we assessed enriched transcription factors among the top gene target predictions from chemical treatment samples in yeast and *Homo sapiens* (MCF7 human cell line) datasets. We compared the performance of DeltaNet with z-score analysis and two network filtering methods, MNI and SSEM. Fig. 1.Workflow of gene target prediction using DeltaNet. The performance of DeltaNet in predicting known gene perturbations was evaluated using gene expression data of *E.coli, S.cerevisiae* and *D.melanogaster*

2.3 Gene expression data
------------------------

For the case studies, we gathered gene expression data from public databases. For *E.coli*, we retrieved microarray data from Many Microbe Microarrays Database (M3D, as of 29th October 2007) (<http://m3d.mssm.edu>) ([@btw148-B12]). More specifically, we obtained the robust multi-array average (RMA)-normalized dataset from the file E_coli_v4_Build_3\_chips524probes4217.tab. As summarized in [Figure 1](#btw148-F1){ref-type="fig"}, the data comprised 4217 genes and 524 samples with 319 samples from gene perturbation experiments, 12 samples from chemical treatments, 55 samples from wild-type control experiments and 138 samples from other conditions (e.g. different growth phases, nutrient feeding strategies). The logFC expression data were computed by subtracting the average of wild-type control experiments from the log-2 RMA intensity data.

For *S.cerevisiae*, we compiled gene expression data from ArrayExpress ([@btw148-B33]) and Gene Expression Omnibus (GEO) ([@btw148-B1]). In order to avoid cross-platform variability, we only used data from *Affymetrix GeneChip Yeast Genome S98*. Among 9335 probe sets, we could match 5117 probe sets to gene symbols using *ygs98.db* package in Bioconductor (Saccharomyces Genome database as of 9th March 2014). As shown in [Figure 1](#btw148-F1){ref-type="fig"}, the yeast dataset consisted of 566 samples, among which 383 samples were from gene perturbation experiments, 36 samples from chemical treatments, 140 samples from wild-type control experiments and 7 samples from other conditions. The raw data were RMA-normalized using *justRMA* function in the *affy* package of Bioconductor ([@btw148-B15]), which provided log-2 normalized intensity. The logFC expression data were again calculated by subtracting the average of all wild-type control samples from the log-2 RMA intensity.

For multicellular organisms, like *Drosophila* and human, the gene expression data should ideally come from the same cell lineage, as the GRN can vary across cell lines. For *D.melanogaster*, we compiled 330 microarray samples of *Affymetrix GeneChip Drosophila Genome 2.0* from ArrayExpress and GEO, of which 80% came from experiments using Schneider 2 (S2) cells and the remaining came from whole-body homogenates. These data originated from five studies involving gene knock-down (KD) and overexpression experiments. In particular, 242 samples came from genetic perturbations and 88 samples were from wild-type control experiments. We mapped the probe sets to GenBank accession number using *drosophila2.db* in Bioconductor (Entrez Gene database as of 17th March 2015). The expression data were again pre-processed using *justRMA* to give log-2 normalized intensity. We noted that the RMA intensities of the controls differed significantly among publications. Therefore, we computed the logFC by subtracting the control data for each publication separately. In order to reduce computational complexity, we only used 6165 probe sets which showed significant differential expression (logFC ≥ 1). By using the median values for multiple probe sets that mapped to one gene, we further reduce the dimension to 5879 genes.

Finally, for human dataset, we compiled 2537 samples of MCF-7 human breast cancer cells from the Connectivity Map (C-Map version 2) ([@btw148-B27]). The expression data were first pre-processed by using *justRMA*, based on which we computed the logFC expression using mean-centering within batches, as recommended in a previous study ([@btw148-B20]). We then selected a subset of 569 samples corresponding to 142 different compound treatments with three or more replicates. The final dataset corresponded to the median logFC expressions among the respective replicates. We mapped 19 846 probe sets from *Affymetrix GeneChip HT Human Genome U133* to GenBank accession number using *hthgu133a.db* in Bioconductor (Entrez Gene database as of 17th March 2015). For computational speed-up, we performed the gene target analysis using only 3153 genes that showed significant differential expressions (\|median logFC\| ≥ 1) in at least one of the treatments.

3 Results
=========

3.1 Predicting network perturbations
------------------------------------

In the first application, we used DeltaNet, MNI, SSEM and *z*-scores to predict the targets of gene perturbation experiments in *E.coli*, yeast, and *Drosophila* datasets. The experiments involved known gene knockouts, over-expression and mutations, which provided the gold standard data for comparing the methods.

The *z*-scores were computed according to: $$z_{ki} = \frac{c_{ki} - {\overline{c}}_{k}}{\sigma_{k}}$$ where $c_{ki}$ is the logFC for gene transcript *k* in sample *i*, ${\overline{c}}_{k}$ and $\sigma_{k}$ are the average and standard deviation of transcript *k* across all samples, respectively. For DeltaNet-LASSO and SSEM, we employed a 10-fold cross validation to determine the optimal *T* as discussed in Methods and Materials. Meanwhile, for DeltaNet-LAR, we used a threshold criterion *δ~r~* of 10%. In the case of MNI, we performed a grid search optimization for each compendium to determine the parameters *Q* and *thP*, which we found to influence the target predictions strongly. Here, we selected the parameter combination giving the minimum average rank error for samples with known perturbations by employing a 5-fold CV. Meanwhile, the parameter *KEEPFRAC* was set such that we retained \>200 genes after the last round of tournament (0.37 for *E.coli*, 0.35 for yeast and 0.33 for *Drosophila*) following the published protocol ([@btw148-B44]). The remaining parameters (*NROUNDS* and *ITER*) were set to their default values. Finally, we used a unit standard deviation for all samples, as this setting gave much better performance than using the recommended sample standard deviation.

The test samples of *E.coli* came from 85 experiments with known perturbations, while the test samples of yeast comprised 109 experiments (see [Supplementary Data](http://bioinformatics.oxfordjournals.org/lookup/suppl/doi:10.1093/bioinformatics/btw148/-/DC1)). For *Drosophila*, the test set came from the study of cell cycle regulators using S2 cells ([@btw148-B4]), comprising 91 different perturbation experiments. [Figure 1](#btw148-F1){ref-type="fig"} gives the numbers of the combined gene targets in the test samples of *E.coli*, yeast, and *Drosophila* test samples, which were slightly higher than the number of samples since a few experiments involved more than one gene perturbation. Except for MNI, we analyzed each sample of experimental replications separately, and used the median value as the final prediction. In the analysis using MNI, we followed the published protocol and used the average gene expression values over replicates as the input data ([@btw148-B44]).

From each method and each test dataset, we obtained a rank list of genes where we sorted the genes in decreasing magnitudes of the perturbation variables $p_{ki}$ (see [Supplementary Data](http://bioinformatics.oxfordjournals.org/lookup/suppl/doi:10.1093/bioinformatics/btw148/-/DC1)). The ranking reflects the confidence level that a gene is directly perturbed in the corresponding experiment, while the sign of $p_{ki}$ indicates the nature of the perturbation. In evaluating the performance of the methods, except for MNI, a true positive (TP) requires not only a high confidence prediction (i.e. large magnitude in $p_{ki}$), but also the correct sign of perturbations (a positive sign for gene induction and a negative sign for gene repression). As MNI did not provide the sign of the perturbations, we only use the gene ranking in evaluating its performance.

[Figure 2](#btw148-F2){ref-type="fig"} compares the true positive rate (TPR) as a function of the gene rank according to DeltaNet, SSEM, MNI and *z*-scores. The TPR was computed as the fraction of the known gene perturbations that appear above a given rank (shown in the *x*-axis). [Figure 2](#btw148-F2){ref-type="fig"} shows that DeltaNet significantly outperformed SSEM, MNI and *z*-scores for all three test datasets. DeltaNet-LAR and DeltaNet-LASSO gave relatively the same TPR. The top 10 genes from DeltaNet had on average 14% and as large as 19% (for *D.melanogaster*) higher TPR than the next best method SSEM. MNI gave the worst TPRs among the methods considered, which could be caused by suboptimal tuning of the parameters. The need to optimize the method parameters for different datasets is a known drawback of MNI, since the tuning of these parameters can be computationally demanding ([@btw148-B9]). Fig. 2.True positive rates of gene target predictions from DeltaNet, SSEM, MNI and z-scores. The results of DeltaNet-LAR came from analyses using a threshold *δ*~*r*~ = 10%

As shown in [Table 1](#btw148-T1){ref-type="table"}, DeltaNet-LAR finished faster than DeltaNet-LASSO and SSEM. The computational time of DeltaNet-LAR decreased with increasing *δ~r~*, as expected. Meanwhile the TPR of DeltaNet-LAR did not vary significantly for *δ~r~* between 1 to 10% (see Supplementary Fig. S1). DeltaNet-LASSO and SSEM had similar computational times since both methods used the same LASSO regularization with 10-fold CV. If the optimal method parameters were known beforehand, then MNI finished quicker than DeltaNet and SSEM. But, as mentioned above, the parameter tuning could lead to a high total computational requirement (see [Table 1](#btw148-T1){ref-type="table"}). Finally, [Table 2](#btw148-T2){ref-type="table"} gives the area under precision-recall (AUPR) and receiver operating characteristic curve (AUROC) for each method, which further confirms the higher accuracy of DeltaNet predictions over those from the other strategies. Table 1**.** Computational times of DeltaNet, SSEM and MNIComputational times[^a^](#btw148-TF1){ref-type="fn"} (h)*E.coli*Yeast*Drosophila*DeltaNet-LAR*δ~r~*= 20%4.349.65.7*δ~r~*= 10%9.7718.89.2*δ~r~* = 5%13.7624.611.4*δ~r~* = 1%17.2029.112.9completion17.9029.913.2DeltaNet-LASSO30.543.842.9SSEM33.848.643.1MNISingle run0.160.190.14Parameter tuning[^b^](#btw148-TF2){ref-type="fn"}15.5815.5511.83[^2][^3] Table 2.AUROC and AUPR of DeltaNet, SSEM, MNI and *z*-scoresAUROCAUPR*E.coli*DeltaNet-LAR[^a^](#btw148-TF3){ref-type="fn"}0.9510.694DeltaNet-LASSO0.9420.717SSEM0.9210.558MNI0.9060.252*Z*-scores0.8600.262*Yeast*DeltaNet-LAR[^a^](#btw148-TF3){ref-type="fn"}0.8900.432DeltaNet-LASSO0.9030.402SSEM0.8930.360MNI0.8760.085*Z*-scores0.8970.233*Drosophila*DeltaNet-LAR[^a^](#btw148-TF3){ref-type="fn"}0.9660.534DeltaNet-LASSO0.9570.527SSEM0.8820.352MNI0.8460.224*Z*-scores0.950.243[^4]

3.2 Predicting transcription factor targets of chemical compounds
-----------------------------------------------------------------

In the second application, we employed the predicted gene targets to identify transcription factors (TFs) which interact with drug and chemical compounds. We used the subset of yeast dataset corresponding to chemical treatments and the human MCF-7 dataset.

For yeast dataset, we employed DeltaNet, SSEM, MNI and *z*-scores analysis to rank gene targets. For DeltaNet-LAR, we used *δ~r~* = 1% in order to keep enough non-zero $p_{ki}$ coefficients. We performed a TF enrichment analysis using the top 100 genes for each chemical treatment sample using Yeastract ([@btw148-B39]), and obtained the adjusted *p*-values of the enriched TFs. We ranked the enriched TFs in increasing *p*-values (i.e. TFs with lower *p-*values are ranked higher).

For evaluating the accuracy of the TF prediction, we used protein-chemical interaction database in Search Tool for Interactions of Chemicals (STITCH) (<http://stitch.embl.de>) ([@btw148-B24]) as a reference. STITCH uses experiments, public database and literature mining as evidence to establish links between chemicals and proteins. In addition, we also used two publications to establish links between TFs and acetate ([@btw148-B16]), and between TFs and rapamycin ([@btw148-B21]). Among the chemical treatment experiments in the yeast compendium, only five compounds have TF interactions in STITCH (with a confidence score \> 0.7). [Figure 3a](#btw148-F3){ref-type="fig"} compares the rankings of known TF targets of these five chemical compounds, according to the adjusted *p-*values from Yeastract for DeltaNet, SSEM, MNI and *z*-scores predictions (see [Supplementary Table S1](http://bioinformatics.oxfordjournals.org/lookup/suppl/doi:10.1093/bioinformatics/btw148/-/DC1) for more details). Here, DeltaNet gave the best median ranking (69.5), followed by SSEM (85), MNI (92.5), and lastly *z*-scores (127). However, differences among the methods were not statistically significant (see [Supplementary Table S2](http://bioinformatics.oxfordjournals.org/lookup/suppl/doi:10.1093/bioinformatics/btw148/-/DC1)). Fig. 3.Rankings of known TF targets of chemical compounds based on TF enrichment analysis of DeltaNet, SSEM, MNI and z-scores predictions. The TFs are ranked according to (a) the adjusted *p*-values of Yeastract for yeast dataset and (b) the combined enrichment scores of Enrichr for human MCF-7 dataset

For MCF7 dataset, we applied DeltaNet, SSEM and *z*-scores to generate the gene target predictions. We could not perform MNI analysis as we had no known perturbations in the MCF7 dataset for parameter tuning. For the TF enrichment analysis, we employed Enrichr ([@btw148-B6]) with the option of position weight matrices using the top 100 predicted gene targets in each sample. Among the drugs in the dataset, only 21 compounds have at least one reported TF target in DrugBank ([@btw148-B42]) and STITCH, which is also in Enrichr. [Figure 3b](#btw148-F3){ref-type="fig"} compares the rankings of the known TF targets of these 21 compounds according to the combined enrichment scores from Enrichr for DeltaNet, SSEM and *z*-scores predictions (see [Supplementary Table S3](http://bioinformatics.oxfordjournals.org/lookup/suppl/doi:10.1093/bioinformatics/btw148/-/DC1) for more details). Again, DeltaNet gave the best median ranking (65), followed by z-scores (83) and SSEM (105). Here, the difference in the median rankings between DeltaNet and SSEM was statistically significant (see [Supplementary Table S2](http://bioinformatics.oxfordjournals.org/lookup/suppl/doi:10.1093/bioinformatics/btw148/-/DC1)). Taken together, the outcomes of TF enrichment analyses above demonstrated that DeltaNet could provide gene target predictions which agreed better with previously reported TFs, than the other methods.

Unfortunately, we could not assess the gene target predictions for the chemical treatment samples from *E.coli* because the chemical compounds, namely ampicillin, kanamycin, norfloxacin and spectinomycin, do not have any TF interactions with high confidence (score \> 0.7) in STITCH.

4 Discussion
============

We developed a method called DeltaNet for predicting the molecular targets of drugs or chemical compounds from gene expression data. Many applications of great interest and importance in drug discovery research, including elucidating the mode of action (MoA) of drugs and the mechanisms of diseases, fall within the problem that is addressed by this work. DeltaNet formulation uses an ODE model of gene transcription process under steady state condition. We employed two strategies for solving the resulting underdetermined linear regression problem: least angle regression (DeltaNet-LAR) and LASSO regularization (DeltaNet-LASSO). One can relax the assumption in DeltaNet which sets $a_{kk}$ to zero, by treating the predicted $p_{ki}$ as the sum between the self-regulatory feedback and the perturbations caused by the treatment. In such a case, instead of using the magnitude of the perturbation coefficients $p_{ki}$ to rank genes, we could use the *q*-values of $p_{ki}$ ([@btw148-B35]). However, for the case studies above, we did not observe any improvement in the prediction accuracy when using gene ranking according to the *q*-values (see [Supplementary Material](http://bioinformatics.oxfordjournals.org/lookup/suppl/doi:10.1093/bioinformatics/btw148/-/DC1) and Supplementary Fig. S2).

The output of DeltaNet comprises a ranked list of gene target predictions. Such a list is amenable for further enrichment analysis to identify other type of molecular targets, such as TFs in the second case study above. An upstream analysis can also be applied to find protein partners of enriched TFs, for example by using Expression2Kinase ([@btw148-B5]) and Enrichr ([@btw148-B6]). Beyond TF and protein targets, one can also apply functional enrichment analysis to obtain the functional relevance of the gene target predictions. Several web-server tools exist for such a purpose, notably ToppCluster analysis ([@btw148-B22]) which provides 17 categories of human-ortholog gene annotations such as gene ontology, pathways, microRNAs and human phenotype.

DeltaNet uses the same ODE model of the gene transcription process as the methods MNI and SSEM, but with a key difference in the manner by which the target predictions are inferred from the data. The first phase of MNI and SSEM involve the identification of the GRN matrix *A* using a compendium of gene expression data. The perturbation matrix *P* is subsequently obtained for the treatment samples of interest by network filtering, which in essence uses the difference $P = C - CA.$ In MNI, the matrix *A* is estimated from training data together with the unknown matrix *P*, using a procedure that resembles Expectation Maximization algorithm ([@btw148-B10]). The convergence of this procedure is however not guaranteed and the solution often varies with the initial starting guess. Also, the performance of MNI is known to sensitively depend on the tuning of method parameters which often leads to numerically intensive optimization ([@btw148-B3]). Not to mention, MNI also requires data from known genetic perturbations for parameter tuning.

In contrast, SSEM uses LASSO regularization to identify the matrix *A* using the complete gene expression data, where the perturbation matrix *P* is initially set to zero. By doing so, SSEM ignores the treatment or perturbation effects when inferring the GRNs. The matrix *P* is subsequently obtained from the residuals of the regression above. The LASSO regularization enforces a limit on the model complexity, an assumption which is based on the observed sparsity of GRNs ([@btw148-B14]; [@btw148-B30]; [@btw148-B38]). The implementation of LASSO requires selecting the appropriate constraint parameter *T* for model complexity. As the optimal value is not known *a priori* and is also problem dependent, a cross-validation is often used for setting *T*. As shown in [Table 1](#btw148-T1){ref-type="table"}, analyses using LASSO, including DeltaNet-LASSO and SSEM, were the slowest among the methods considered. Here, the majority of the computational time was contributed by the cross validation step.

One can view DeltaNet as a hybrid between MNI and SSEM. The inference of the matrices *A* and *P* in DeltaNet is performed simultaneously, which resembles the first step of MNI. But, like SSEM, we employed a GRN sparsity assumption by way of LAR and LASSO regularization to tackle the underdetermined problem. Nevertheless, DeltaNet does not involve an explicit network filtering step. Instead, the perturbation matrix *P* for the treatment samples is obtained together with the other samples in the compendium. We could therefore fully use the information contained in the available data (training and treatment sets) in predicting the effects of a treatment. As demonstrated in the case studies, DeltaNet offers a significant improvement in the accuracy of target prediction over MNI and SSEM. Furthermore, DeltaNet-LAR has better numerical efficiency and robustness with respect to parameter tuning over DeltaNet-LASSO, MNI and SSEM. We therefore recommend DeltaNet-LAR using a threshold parameter *δ~r~* of 10%, since in our experience, this setting provides a good balance between target prediction accuracy and computational performance.

While the difference between DeltaNet and the existing network filtering methods may appear slight, this deviation is nevertheless important and fundamental. There were two key factors motivating the single-step inference in DeltaNet. First, the inference of GRNs from the typical gene expression has been shown to be underdetermined ([@btw148-B36]; [@btw148-B41]). Thus, any method relying on the solution of such an inference problem could be sensitive to the associated uncertainty. Second, despite the underdetermined issue, it is often possible to predict the effects of a network perturbations from existing gene expression data with reasonable accuracy ([@btw148-B31]). We formulated DeltaNet based on the premise that the available gene expression data, while lacking information for the accurate inference of GRN, have enough information to identify the network perturbations caused by a treatment.

The differences between the gene target predictions from DeltaNet-LASSO and SSEM are quite interesting, considering that both methods employ the same LASSO regularization. In the first case study, we noted that for yeast and *E.coli* datasets, DeltaNet-LASSO produced sparser GRNs than SSEM (see Supplementary Fig. S3a). This trend is expected since in comparison to SSEM, DeltaNet formulation has additional degrees of freedom that come from the perturbation vector. However, the network sparsity between DeltaNet and SSEM in the *Drosophila* dataset did not differ significantly. We further looked at the set of known gene targets among the top 10 predictions from DeltaNet-LASSO, but not from SSEM. For these gene targets (*n* = 10, 15 and 13 for *E.coli*, yeast and *Drosophila*, respectively), DeltaNet-LASSO clearly produced fewer non-zero coefficients than SSEM for all three datasets (see Supplementary Fig. S3b). The observations above indicated a possibility of overfitting in SSEM as the regression problem did not consider perturbations on the genes.

Finally, time-series expression data have become routine and increasingly available in public databases. Applying DeltaNet and similar methods such as SSEM and MNI to time series data should be done with caution because of the underlying steady state assumption in the method formulation. In the case studies, we included time-series data as a part of the training dataset. Excluding time-series data however did not affect the accuracy of DeltaNet predictions significantly (see Supplementary Fig. S4). An extension of DeltaNet to take advantage of time-series data is currently being developed, the results of which will be reported in a separate publication.
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